We are proud to announce that Ralph Tripp, PhD, University of Georgia professor and TrippBio’s Chief Science Officer has been invited by the FDA to join the Advisory Committee of independent medical experts who will review and then vote to recommend the Emergency Use Authorization of the first COVID-19 vaccine in the USA.
“I’m honored to be part of this process and look forward to reviewing the data with my peers,” said Dr. Tripp.
The committee meets today, December 10, and the FDA is expected to provide its decision soon after.
“The fact that Ralph was invited to join this prestigious group of medical advisors is testimony to his standing and profound expertise in infectious diseases,” stated TrippBio CEO & President, Philip Young. “At TrippBio, we are hopeful that our continued work in the space of COVID-19 therapeutics, coupled with the authorization and distribution of vaccinations in 2021, will help enable the world to better manage this pandemic and improve patient outcomes around the globe.”
